David Craig's The New Rules of Biotech: A Founder's Guide to Building Great Companies is now available in hardcover ($29.99) and as an audiobook on Google Play, joining the existing paperback and Kindle editions. The book addresses the current biotech landscape, where capital is expensive, FDA requirements have shifted, and the Inflation Reduction Act has altered drug economics. Craig, founder of Sarcomatrix Therapeutics, draws on his experience to offer practical advice on company building, from choosing between platforms and assets to raising seed rounds and using non-dilutive capital strategically.
The book is intended for founders, investors, board members, and operators, with each chapter including takeaways for operators and separate insights for investors. The audiobook allows listeners to absorb the material on the go. Craig emphasizes building for the current market, not the one that existed in 2021. The hardcover edition is available at Amazon, along with the paperback and Kindle versions. The audiobook is accessible via Google Play.
The book's origin stems from Craig's personal connection to a rare genetic muscle disease, RYR-1 related congenital muscular dystrophy, which informs his argument that biotech company building carries societal responsibility. Craig has worked in the pharmaceutical and biotechnology industry since 1986, with experience in drug development, company building, and investing. The New Rules of Biotech is his first book, published by D. Craig Consulting LLC.
